Mersana Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $504.48 million
- Book Value:
- Revenue TTM:
- $26.58 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Mersana Therapeutics Inc had its IPO on 2017-06-28 under the ticker symbol MRSN.
The company operates in the Healthcare sector and Biotechnology industry. Mersana Therapeutics Inc has a staff strength of 228 employees.
Shares of Mersana Therapeutics Inc opened at $4.82 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $4.53 - $4.87, and closed at $4.67.
This is a -3.51% slip from the previous day's closing price.
A total volume of 3,288,400 shares were traded at the close of the day’s session.
In the last one week, shares of Mersana Therapeutics Inc have slipped by -11.05%.
Mersana Therapeutics Inc's Key Ratios
Mersana Therapeutics Inc has a market cap of $504.48 million, indicating a price to book ratio of 7.1434 and a price to sales ratio of 57.8327.
In the last 12-months Mersana Therapeutics Inc’s revenue was $26.58 million with a gross profit of $-146804000 and an EBITDA of $-202840000. The EBITDA ratio measures Mersana Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mersana Therapeutics Inc’s operating margin was -766.59% while its return on assets stood at -47.13% with a return of equity of -191.03%.
In Q4, Mersana Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 133427.3%.
Mersana Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mersana Therapeutics Inc’s profitability.
Mersana Therapeutics Inc stock is trading at a EV to sales ratio of 32.8674 and a EV to EBITDA ratio of -1.9173. Its price to sales ratio in the trailing 12-months stood at 57.8327.
Mersana Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $334.34 million
- Total Liabilities
- $91.53 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Mersana Therapeutics Inc ended 2023 with $334.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $334.34 million while shareholder equity stood at $92.06 million.
Mersana Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $91.53 million in other current liabilities, 11000.00 in common stock, $-654691000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $128.89 million and cash and short-term investments were $280.71 million. The company’s total short-term debt was $2,798,000 while long-term debt stood at $24.93 million.
Mersana Therapeutics Inc’s total current assets stands at $319.22 million while long-term investments were $0 and short-term investments were $151.83 million. Its net receivables were $30.00 million compared to accounts payable of $13.95 million and inventory worth $0.
In 2023, Mersana Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $785000.
Comparatively, Mersana Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Mersana Therapeutics Inc stock is currently trading at $4.67 per share. It touched a 52-week high of $8.338 and a 52-week low of $8.338. Analysts tracking the stock have a 12-month average target price of $16.83.
Its 50-day moving average was $5.9 and 200-day moving average was $6.14 The short ratio stood at 6.17 indicating a short percent outstanding of 0%.
Around 122.7% of the company’s stock are held by insiders while 9845.3% are held by institutions.
Frequently Asked Questions About Mersana Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.